ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0330

Temporal Changes in Atrial Fibrillation and Atrial Flutter Prevalence in Patients with ESKD Following Arteriovenous Fistula Placement

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical

Authors

  • Djanie, Thermutis, Albany Medical College, Albany, New York, United States
  • Thomas, Taniya, Albany Medical College, Albany, New York, United States
  • Daghstani, Omar, Albany Medical College, Albany, New York, United States
  • Hongalgi, Krishnakumar D., Albany Medical College, Albany, New York, United States
  • Torosoff, Mikhail, Albany Medical College, Albany, New York, United States
Background

End-stage kidney disease (ESKD) patients have a high burden of cardiovascular disease, including hypertension, congestive heart failure, and coronary artery disease, which are known risk factors for atrial fibrillation and atrial flutter (AF/AFL). While the prevalence and predictors of AF/AFL have been studied in various populations, their occurrence and evolution in patients with ESKD remains unclear.

Methods

We conducted a retrospective cohort study in 196 consecutive ESKD patients who underwent arteriovenous (AV) fistula placement. The prevalence and predictors of AF/AFL were analyzed before and after AV fistula placement. The study was approved by the Institutional Review Board (IRB).

Results

The study population included 40% females, 60.7+/-14.6 years old, with BMI 28.3+/-6.6 and histories of hypertension (HTN) in 91.3%, coronary artery disease (CAD) in 46.9%, atrial fibrillation in 35.2%, diabetes mellitus (DM) in 63.7%, and congestive heart failure (CHF) in 50%. The maximum time difference between the first and the second ECGs was 137 months, with a mean of 34+/-27 months.
At baseline, patients with AF/AFL were significantly older (p<0.001) and had a prior history of AF/AFL (p<0.001), while traditional arrhythmia risk factors, e.g. HTN, CAD, DM, or CHF were not associated with arrhythmia. During the study interval, ESKD patients experienced a 3-fold increase in the prevalence of AF/AFL after AV fistula placement, from 4% on baseline to 11% on the follow-up ECGs (p<0.001). At the follow-up and after AV fistula placement, none of the traditional AF/AFL risk factors were linked with arrhythmia.

Conclusion

Prevalence of AF/AFL is significantly increased in ESKD patients following AV fistula placement. Traditional risk AF/AFL predictors do not appear to be important in these ESKD patients. Further studies of effects of AV fistula placement on arrhythmia are warranted in ESKD patients.

Digital Object Identifier (DOI)